From the Wires
Phase 3 Topical Drug for Raynaud's Disease Available for Licensing/Acquisition at the J.P. Morgan Conference
By: PR Newswire
Dec. 13, 2012 01:23 PM
BOTHELL, Wash., Dec. 13, 2012 /PRNewswire-iReach/ -- MediQuest Therapeutics Inc., a specialty pharmaceutical company focused on inflammatory skin diseases and conditions, today announced that they will be conducting partnering/M&A meetings at the J.P. Morgan 31st Annual Healthcare Conference between January 7th and 10th in San Francisco, regarding its Phase 3 topical formulation, VASCANA, designed to treat Raynaud's Disease, an unmet medical need. MediQuest is also selling/licensing the remainder of its topical assets including a skin lightener, ready for commercialization. Its topical/non-systemic Onychomycosis drug was out-licensed in August 2012.
MediQuest's VASCANA has a Special Protocol Assessment granted by the Federal Food & Drug Administration for a single Phase 3 study involving approximately 150 patients that suffer from moderate to severe symptoms of Raynaud's Syndrome. VASCANA has a strong safety profile and an extensive intellectual property portfolio with issued patents that run to 2026. The peak sales in the United States is estimated at about $250 million, as well as similar markets in EU and Asia, with low cost of goods, supported by 2-years of stability data.
Any company interested in learning more about VASCANA can arrange to meet with MediQuest at the J.P. Morgan conference through the below contact information.
About Raynaud's Disease
About MediQuest Therapeutics, Inc.
Media Contact: Siavash Forootan MediQuest Therapeutics, 215-238-8881, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE MediQuest Therapeutics, Inc.
Latest AJAXWorld RIA Stories
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week